ORGANIC
LETTERS
2007
Vol. 9, No. 23
4753-4756
Synthesis of (E)- and
(Z)- -Alkylidene- -aryl-γ-butyrolactones
r
γ
via Alkenylalumination of Oxiranes
P. Veeraraghavan Ramachandran,* Garrett Garner, and Debarshi Pratihar
Department of Chemistry, Purdue UniVersity, 560 OVal DriVe,
West Lafayette, Indiana 47907-2084
Received August 23, 2007
ABSTRACT
Alkenylalumination of substituted styrene oxides with [
corresponding (Z)- -alkylidene- -aryl- -hydroxy esters in 81
with trifluoroacetic acid, provides isomerically pure (Z)- -alkylidene-
alkylidene hydroxyl esters using LDA, followed by protonation using a bulky proton source, such as BHT, provides a simple route to the
r
-(ethoxycarbonyl)alkenyl]diisobutylaluminum, in the presence of BF3
100% Z-selectivity. Chromatographic separation of isomers, followed by lactonization
-aryl- -butyrolactones in 53 78% overall yield. Isomerization of the (Z)-
‚Et2O, affords the
r
γ
γ
−
r
γ
γ
−
corresponding
r-(E)-alkylidene-γ-phenyl-γ-hydroxy esters in 72−78% yield, which were cyclized to obtain the corresponding (E)-butyrolactones
in 78 85% yield.
−
Interest in naturally occurring and synthetic R-alkylidene-
γ-butyrolactones is surging1 as several of them have been
identified to display anti-inflammatory COX-2 inhibition, as
well as phytotoxic and cytotoxic activities.2 The binding of
a series of suitably substituted γ-butyrolactones, particularly,
γ-substituted-R-alkylidene-γ-butyrolactones, which are ana-
logues of diacylglycerol (DAG) lactones, to protein kinase
C (PK-C) displays an enhanced affinity due to the R-alkyli-
dine group.3 This family of lactones has also been tapped
for their potential as versatile synthons.4 Even though there
are several protocols for their synthesis,1,5 very few offer
simple, direct routes.
We had previously reported the preparation of (Z)- or (E)-
R-alkylidene-γ-alkyl-γ-butyrolactones via a crotylboration-
oxonia-Cope process.6 This method is restricted to the
preparation of γ-alkyl derivatives since γ-aryl derivatives
undergo a carbocation-mediated rearrangement to provide
cis- or trans-â,γ-disubstituted-R-methylene-γ-butyrolactones
(4) Oh, S.; Jeong, I. H.; Shin, W.-S.; Wang, Q.; Lee, S. Bioorg. Med.
Chem. Lett. 2006, 16, 1656.
(5) (a) Katsumi, I.; Kondo, H.; Yamashita, K.; Hidaka, T.; Hosoe, K.;
Yamashita, T.; Watanabe, K. Chem. Pharm. Bull. 1986, 34, 121. (b)
Shaikenov, T. E.; Adekenov, S. M.; Williams, R. M.; Baker, F. L.; Prasad,
N.; Madden, T. L.; Newman, R. Oncol. Rep. 2001, 8, 173. (c) Nattrass, G.
S.; Diez, E.; McLachlan, M. M.; Dixon, D. J.; Ley, S. V. Angew. Chem.,
Int. Ed. 2005, 44, 580. (d) Biel, M.; Kretsovali, A.; Karatzali, E.;
Papamatheakis, J.; Giannis, A. Angew. Chem., Int. Ed. 2004, 43, 3974. (e)
Gonzalea, A. G.; Silva, M. H.; Pardon, J. I.; Leon, F.; Reyes, E.; Alvarez-
Mon, M.; Pivel, J. P.; Quintana, J.; Estevez, F.; Bermejo, J. J. Med. Chem.
2002, 45, 2358. (f) Trost, B. M.; Corte, J. R. Angew. Chem., Int. Ed. 1999,
38, 3664. (g) Trost, B. M.; Corte, J. R.; Gudiksen, M. S. Angew. Chem.,
Int. Ed. 1999, 38, 3662.
(1) (a) Tesaki, S.; Kikuzaki, H.; Yonemori, S.; Nakatani, N. J. Nat. Prod.
2001, 64, 515. (b) Moise, J.; Arseniyadis, S.; Cossy, J. Org. Lett. 2007, 9,
1695 and references cited therein. (c) Raju, R.; Allen, L.; Le, T.; Taylor,
C.; Howell, A. Org. Lett. 2007, 9, 1699. (d) Oh, S.; Jeong, I. H.; Shin,
W.-S.; Wang, Q.; Lee, S. Bioorg. Med. Chem. Lett. 2006, 16, 1656.
(2) (a) Janecki, T.; Blaszczyk, E.; Janecka, A.; Krajewaska, U.; Rozalski,
M. J. Med. Chem. 2005, 48, 3516. (b) Huang, W. C.; Chan, S. T.; Yang,
T. L.; Tzeng, C. C.; Chen, C. C. Carcinogenesis 2004, 25, 1925.
(3) (a) Kang, J. H.; Peach, M. L.; Pu, Y.; Lewin, N. E.; Nicklaus, M.
C.; Blumberg, P. M.; Marquez, V. E. J. Med. Chem. 2005, 48, 5738. (b)
Tamamura, H.; Bruno, B.; Nacro, K.; Nancy, E. L.; Blumberg, P. M.;
Marquez, V. J. Med. Chem. 2000, 43, 3209.
(6) Ramachandran, P. V.; Pratihar, D. Org. Lett. 2007, 9, 2087.
10.1021/ol702079f CCC: $37.00
© 2007 American Chemical Society
Published on Web 10/18/2007